



ASX & Media Release

Patrys' Deoxymab 3E10 patent granted in the U.S.

- First 3E10 cancer treatment patent has been granted in United States, providing protection on the technology to April 2031
- Patent covers 3E10 variants, including Patrys' lead candidate PAT-DX1, for treatment for several challenging cancers
- Granting of patent triggers milestone payment of \$180,000, as Patrys shares, to the vendors of Nucleus Therapeutics

Melbourne, Australia; July 12, 2017: Patrys Limited (**ASX: PAB**), a therapeutic antibody development company, is pleased to announce that it has received a Notice of Grant from the United States Patent and Trademark Office (USPTO) for the patent application titled “ Cell-penetrating anti-DNA antibodies and uses thereof to inhibit DNA repair” (granted patent no. 9,701,740). The patent protects the method of use of Patrys' novel Deoxymab 3E10 family, including Patrys' lead candidate, PAT-DX1, as treatment for various cancers.

“The granting of the first U.S. patent protecting the use of Deoxymab 3E10 marks a significant milestone for Patrys, and secures the development and commercialisation rights for PAT-DX1 at an exciting time for the company. Having selected a lead candidate, initiated pre-clinical studies, and secured non-dilutive funding over the past several months, the company is building a strong position at the forefront of nuclear-penetrating antibody therapeutics,” said Dr James Campbell, Chief Executive Officer and Managing Director of Patrys. “The scope and timeliness of the granted patent attests to the novelty of 3E10 and its variants and provides a solid foundation for their commercial development.”

This patent grant initiates the second tranche payment to the original shareholders of Nucleus Therapeutics, and will result in the issue of Patrys shares to satisfy the second tranche payment of A\$180,000. A third and final tranche, also worth of A\$180,000 will be triggered upon the first dosing of a patient in a phase 1 clinical trial with therapeutics from the Deoxymab family.

For the purposes of ASX Listing Rule 3.10.3, Patrys advises that it proposes to issue a maximum of 34,789,331 fully paid ordinary shares (ranking equally with ordinary shares on issue) at a price of 0.5174 cents per share to Nucleus shareholders in connection with the second tranche payment of the Nucleus Therapeutics acquisition announced on 29 March 2016. No shareholder approval will be sought in relation to this proposed issue.



About Deoxymab 3E10 and PAT-DX1

Patrys has a worldwide license to develop and commercialise as anti-cancer agents a portfolio of pre-clinical novel anti-DNA antibodies and antibody fragments/variants and antibody-nanoparticle conjugates discovered at Yale University.

Deoxymab 3E10 is an autoantibody originally identified in models of lupus. Unlike normal antibodies that bind to foreign cells (eg pathogens) or aberrant cells (eg cancer cells) and trigger an immune response, autoantibodies bind to normal cells. Of particular interest with Deoxymab 3E10 is that whilst most antibodies bind to markers on the surface of cells, Deoxymab 3E10 penetrates cells' nuclei and binds directly to DNA. Having bound to the DNA, Deoxymab 3E10 inhibits DNA repair and damages DNA. Normal cells repair DNA damage utilising intact DNA repair processes, however Deoxymab 3E10 can kill cells that have mutations or deficiencies in DNA repair mechanisms as found in various cancer cells. As well as showing single agent therapeutic potential Deoxymab 3E10 has been shown to significantly enhance the efficacy of both chemo- and radiotherapies.

Patrys has selected a high-performing variant of Deoxymab 3E10, PAT-DX1 as the lead candidate from the program and is progressing PAT-DX1 into pre-clinical cancer models. Patrys believes that PAT-DX1 may have application across a wide range of malignancies such as gliomas, melanomas, prostate, breast, pancreatic and ovarian cancers.

-Ends-

For further information, please contact:

Patrys Limited:

James Campbell
Chief Executive Officer
P: +61 3 96703273
info@patrys.com

Patrys IR:

Kyahn Williamson
Buchan Consulting
P: +61 3 9866 4722
kwilliamson@buchanwe.com.au

Patrys Media:

Kellie Stanborough
Buchan Consulting
P: +61 3 9866 4722
kstanborough@buchanwe.com.au

About Patrys Limited:

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found at www.patrys.com.